Sana (SANA) Surges 14.5% Ahead of Business Announcements

We recently published 10 Small Stocks with Mighty Gains. Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the top-performing stocks on Wednesday.

Sana Biotechnology soared by 14.53 percent on Wednesday to finish at $4.02 apiece as investors loaded portfolios ahead of its business updates next week.

In a statement, Sana Biotechnology, Inc. (NASDAQ:SANA) said that its president and chief executive officer, Steve Harr, would present the company’s business overview and update at the Citi 2025 Global Healthcare Conference on Tuesday, December 2, as well as the 8^th Annual Evercore Healthcare Conference on Wednesday, December 3.

Investors will be closely watching out for updated outlooks, particularly for SC451 and SG293—its drug candidates for the treatment of diabetes, as well as B-Cell cancer and autoimmune diseases, respectively.

Earlier this month, Sana Biotechnology, Inc. (NASDAQ:SANA) said that it would prioritize its operations in the development of the two treatments.

Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company focused on creating and delivering engineered cells as medicines.

In the third quarter of the year, the company narrowed its net loss by 30 percent to $42.15 million from $59.92 million in the same period last year.

Total operating expenses also dwindled by 29.5 percent to $43.51 million from $61.76 million year-on-year.

While we acknowledge the potential of SANA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.